{"slideshow_credits": null, "snippet": "Bill Ackman has led something of a crusade on moral grounds against Herbalife, a nutritional supplements company, but he seems unperturbed by Valeant&#8217;s rapacious re-pricing of old drugs.", "abstract": "Andrew Ross Sorkin DealBook column contends activist investor William A Ackman, head of Pershing Square Capital Management, has confounding and sometimes contradictory views on investing; contrasts his crusade against nutritional supplements firm Herbalife and his investment in Valeant, which is under investigation for drug pricing.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"lastname": "SORKIN", "rank": 1, "firstname": "Andrew", "role": "reported", "organization": "", "middlename": "Ross"}], "original": "By ANDREW ROSS SORKIN"}, "web_url": "http://www.nytimes.com/2015/11/10/business/dealbook/ackmans-enigmatic-investment-philosophy.html", "lead_paragraph": "Bill Ackman has led something of a crusade on moral grounds against Herbalife, a nutritional supplements company, but he seems unperturbed by Valeant&#8217;s rapacious re-pricing of old drugs.", "headline": {"print_headline": "Ackman&#8217;s Enigmatic Investment Philosophy ", "main": "Bill Ackman\u2019s Enigmatic Approach to Valeant Pharmaceuticals", "content_kicker": "DealBook", "kicker": "DealBook Column"}, "_id": "5641515138f0d80e74ff97e3", "word_count": "1101", "multimedia": [{"height": 126, "url": "images/2015/11/10/business/10DB-SORKINjp/10DB-SORKINjp-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/11/10/business/10DB-SORKINjp/10DB-SORKINjp-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 399, "url": "images/2015/11/10/business/10DB-SORKINjp/10DB-SORKINjp-articleLarge.jpg", "legacy": {"xlarge": "images/2015/11/10/business/10DB-SORKINjp/10DB-SORKINjp-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "399"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/11/10/business/10DB-SORKINjp/10DB-SORKINjp-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/11/10/business/10DB-SORKINjp/10DB-SORKINjp-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-11-10T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "persons", "value": "Ackman, William A", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "is_major": "Y", "rank": "2"}, {"name": "organizations", "value": "Herbalife Ltd", "is_major": "Y", "rank": "3"}, {"name": "organizations", "value": "Pershing Square Capital Management", "is_major": "Y", "rank": "4"}, {"name": "subject", "value": "Ethics (Personal)", "is_major": "N", "rank": "5"}, {"name": "subject", "value": "Stocks and Bonds", "is_major": "N", "rank": "6"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "7"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}